AMSS News & Events

Amass Brands files to sell 8.95M shares of common stock for holders

Amass Brands announced that it has entered into a simple agreement for future equity, or SAFE, in Afterdream, representing the right to receive at least a 15.67% ownership interest in Afterdream on a fully diluted basis upon a future qualifying financing or liquidity event. The transaction was structured as a SAFE, an instrument that enables both parties to complete the investment without requiring a formal valuation of Afterdream at this stage. The SAFE converts into equity upon a future qualifying financing or triggering event, and does not result in the issuance of shares or stockholder dilution prior to conversion. Unlike a convertible note, the instrument carries no interest rate, maturity date, or repayment obligation. In the event of a dissolution or liquidity event occurring prior to conversion, the SAFE entitles Amass to receive the greater of its invested amount or its as-converted equity value, a preference that ranks senior to the rights of common stockholders.

Kardigan shares jumped on Thursday after the heart-health focused biotech raised $400M in an initial public offering. The stock opened at $16.25 and closed its first day of trade near $22 per share.LATEST IPOS AND DIRECT LISTINGS:Kardigan, a clinical-stage precision therapeutics company developing medicines that target cardiovascular diseases, opened at $16.25 on June 18 after having priced its upsized initial public offering of 25M ordinary shares at a public offering price of $16 per share. The deal size was increased to 25M from 23.3M shares and priced at the high end of the $14-$16 range.Deep Fissionopened at $16 on June 18 after the advanced nuclear energy company priced 2.5M shares at $16.00. The deal range was $16.00-$18.00. Deep Fission is developing small modular pressurized water reactors installed one mile underground.First Carolinaopened at $13.25 on June 18 after having priced 5.5M shares at $12.50. The deal priced below the $14.00-$16.00 target range. First Carolina Financial Services, the holding company for First Carolina Bank, intends to use the net proceeds from the offering for general corporate purposes, which may include supporting organic growth, potential acquisitions, refinancing of outstanding indebtedness, and working capital.PERFORMANCE:Prices as of 1:30 pm ET on Monday, June 22 -Kardigan - up $1.30 to $23.30Deep Fission - down $1.12 to $13.44First Carolina Financial Services - down 5c to $12.56RECENT IPOS TO WATCH:SpaceXand Conexeu Scienceshave already seen some coverage roll out, while AMASS Brandsand Optimi Healthare among stocks that could see new coverage shortly as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include Bending Spoons, Inspire Brands, and Tarsier Pharma. Clickto see the upcoming IPO calendar on TipRanks.Bending Spoons, a technology company whose main businesses include AOL, Brightcove, Eventbrite, Evernote, Harvest, komoot, Remini, StreamYard, Vimeo, and WeTransfer, announces that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol "BSP."Inspire Brandsannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Inspire Brands expects to use the net proceeds of the proposed offering to repay outstanding indebtedness under its existing term loan facility and pay offering fees and expenses.Tarsier Pharma Ltd.filed for an initial public offering of its ordinary shares and applied to list its ordinary shares on the NYSE American under the symbol "TARX". Tarsier is developing TRS01 and TRS02, novel product candidates based on dazdotuftide, a new molecule with a new mechanism of action for uveitis and uveitic glaucoma.Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.